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Abstract 
In mammalian systems “sterolomics” can be regarded as the quantitative or semi-quantitative 
profiling of all metabolites derived from cholesterol and its cyclic precursors. The system can be 
further complicated by metabolites derived from ingested phytosterols or pharmaceuticals, but this 
is beyond the scope of this article. “Sterolomics” can be performed on either an unbiased global 
format, or more usually, exploiting a targeted format. Here we discuss the different mass 
spectrometry-based analytical techniques used in “sterolomics” giving specific examples in the 
context of neurodegenerative disease and for the diagnosis of inborn errors of metabolism. We pay 
particular attention to the profiling of cholesterol metabolites in the bile acid biosynthesis pathways, 
although the analytical techniques discussed are also appropriate for analysis of hormonal steroids.         
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Mass spectrometry, liquid chromatography – mass spectrometry, gas chromatography – mass 
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oxysterols 
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1. Introduction 
Sterols are one of the eight classes of lipids defined by the Lipid Maps classification system [1]. This 
class includes cholesterol and its relatives built on the cholestane skeleton, including steroids where 
the 8-carbon side-chain of cholesterol is shortened, bile acids where the terminal carbon of the side-
chain has a carboxyl function, oxysterols oxidised forms of cholesterol maintaining the 8-carbon 
side-chain and ring-opened seco-sterols including vitamins D3 (Figure 1). The profiling of the sterol 
content of a system can be regarded as “sterolomics”, which is a subdivision of both “lipidomics” 
and “metabolomics”. Sterols are usually under-represented in un-targeted lipidomic and 
metabolomic studies [2] due to their poor ionisation characteristics and the dominating 
concentration of cholesterol and its esters. This has driven the development of “sterolomics” where 
sample purification schemes have been developed to specifically enrich for sterols [3, 4]. 
2. Technology 
The dominating technology in “sterolomics” is mass spectrometry (MS)-based, although nuclear 
magnetic resonance spectrometry is unsurpassed for exact stereochemical identification of sterols. 
In an “omics” setting direct-infusion (DI)-MS, liquid chromatography (LC)-MS, matrix-assisted laser 
desorption/ionisation (MALDI)-MS, gas chromatography (GC)-MS and more recently ion-mobility-MS 
(IMS) and MS-imaging (MSI) all have their place for determining the global sterolome. 
2.1. GC-MS 
GC-MS has been used for decades for sterol profiling, well before the initiation of the “omics” 
revolution [5, 6]. It is still widely used for analysis of bile acids [7], steroids [8], cholesterol and its 
precursors [9] and oxysterols [10]. Many of the current methods are based on classical protocols 
developed in the laboratories of Sjövall [3, 6], Shackleton  [11] and Björkhem [12, 13]. A pre-requisite 
for GC-MS analysis of sterols is derivatisation to enhance volatility and stability. Hydroxy groups are 
usually converted to trimethylsilyl ethers, carbonyls to methyloximes and carboxylic acid groups are 
methylated. Additionally, aminoacyl conjugated bile acids and steroid sulphates are enzymatically 
deconjugated (enzymes from Clostridium perfringens and Helix promatia, respectively) while sterols 
esterified with fatty acyl groups are hydrolysed or when esterified with sulphuric acid subjected to 
solvolysis [3, 11]. The requirements of de-conjugation and derivatisation have encouraged the 
movement from GC-MS to MS methods utilising desorption ionisation processes, including MALDI 
and the atmospheric pressure ionisation (API) method of electrospray ionisation (ESI). 
2.2 DI-MS 
DI-MS is an important technology used for screening for inborn errors of metabolism as discussed in 
section 3.2. It has its origin in the classical work using fast-atom bombardment (FAB)-MS developed 
in the laboratories of Shackleton [11], Setchell  [3] and Clayton [14] and is a precursor to “shotgun” 
lipidomics. In brief, samples are prepared targeting the physicochemical properties of the analytes of 
interest and infused into the MS, today exploiting ESI, with or without tandem mass spectrometry 
(MS/MS). DI-MS works most effectively for acidic or basic analytes like bile acids, steroid-sulphates 
or -glucuronides, or sulphates of cholesterol and oxysterols. The large changes in sterol patterns as a 
consequence of a defective enzyme in cholesterol biosynthesis or metabolism often makes diagnosis 
possible from a simple mass spectrum. Due to an absence of chromatographic separation in DI-MS 
mixtures of isomers are not resolved and diagnosis is based on semi-quantitative measurements or 
pattern recognition of MS-peaks. Definitive diagnosis is achieved by sequencing of the gene coding 
for the suspected defective enzyme.  
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2.3. LC-MS 
LC-MS using ESI allows the analysis of polar and involatile sterols often making hydrolysis and 
derivatisation steps unnecessary. The ease of interfacing LC with API sources, particularly with ESI, 
allows the exploitation of on-line LC, making a once very challenging technology now routine. With 
the advent of commercial ultra-high-performance LC (UHPLC) systems, allowing back pressures of 
1000 bar, and adoption of columns packed with sub-2 µm particles, high resolution chromatographic 
separation is now possible [15, 16]. To gain sensitivity for the LC-MS analysis of precious samples 
low-flow-rate-LC-MS methods are available. Capillary- (< 1 mm i.d.) and nano- (<100 µm i.d.) 
dimension columns with flow-rates of 20 – 0.1 µL/min provide the benefits of concentration-
dependent ESI [11, 17, 18]. 
2.4. MALDI-MS and -MSI 
MALDI-MS provides for another version of “shotgun” lipidomic and is being used in an increasing 
number of studies profiling sterols, including steroids and bile acids [19, 20]. However, it is in the 
realm of MALDI-MSI that the most exciting studies are being made [21-26]. Due to their 
comparatively poor ionisation characteristics neutral sterols have often been derivatised to enhance 
their signal in MS analysis. In particular, the Girard hydrazine reagents have been exploited for 
analysis of sterols possessing an oxo-group, originally by FAB-MS, and latterly by ESI-MS and MALDI-
MS (Figure 2) [17, 18]. Theses reagents effectively tag a positive-charge to the sterol, hugely 
enhancing sensitivity. Andrew’s group in Edinburgh and Ito’s group in Osaka have applied the Girard 
T (GT) reagent to tissue material followed by matrix and proceeded to perform MALDI-MSI for GT-
derivatised steroids. Shimma et al used this method to visualise testosterone in testis tissues of mice 
treated with human chorionic gonadotropin [25], while Cobice et al, also using the GT reagent, 
imaged steroids in mouse testis for testosterone and 5α-dihydrotestosterone at a resolution of 150 – 
50 µm and sensitivity of 0.1 pg [24]. 
2.5. Liquid-extraction for surface analysis (LESA)-ESI-MSI 
The concept of LESA for MSI derives from the work of Kertesz and Van Berkel and colleagues [27] 
and has been cleverly exploited with on-tissue derivatisation in the area of “sterolomics” by Cobice 
et al [23, 24]. The concept behind LESA is that a liquid micro-junction is created between a sampling 
pipette, or capillary tip, and a surface, analytes partition between the surface and the liquid which is 
then withdrawn and transported, either mechanically, or on-line, to an ESI emitter for MS analysis 
[27]. Cobice et al used on-tissue derivatisation with the GT reagent and analysed distinct regions of 
mouse brain for corticosteroids [23] and androgens in mouse testis [24]. While early versions of LESA 
achieved resolutions of 1 – 2 mm, newer versions can achieve resolutions of < 0.4 mm and be 
coupled on-line with LC. 
2.6. Desorption electrospray ionisation (DESI) -MS and -MSI 
DESI was introduced by Cooks and colleagues in Purdue in the early part of this century [28]. In brief, 
electrically charged droplets are electrosprayed at a target of interest under ambient conditions. 
Secondary ions generated from collisions of the charged droplets with the target are then sampled 
by the MS at atmospheric pressure. A variant of DESI is reactive DESI where a reactive reagent is 
incorporated in the spray solvent. Reactive-DESI has been utilised in a number of “sterolomic” 
investigations [29, 30]. A particularly impressive application of reactive DESI is for the MSI of 
cholesterol in rat brain using betaine aldehyde in the spray solvent [30]. 
3. Applications 
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3.1. Neuroscience and Neurodegeneration 
About 25% of unesterified cholesterol is located in the central nervous system (CNS) of mammals 
[31], so it is not surprising that sterols are linked with neurological disorders. Cholesterol cannot pass 
the blood brain barrier (BBB), which is formed prenatally, and after birth essentially all cholesterol in 
the CNS is synthesised in situ. Excess cholesterol in the CNS is removed by metabolism, mostly to 
24S-hydroxycholesterol (24S-HC, Figure 3) which can pass the BBB. The BBB is permeable to 
oxysterols and cholestenoic acids which can pass into and out of the CNS [32]. 
3.1.1. Alzheimer’s Disease (AD) and Parkinson’s Disease (PD)  
Apolipoprotein E (APOE) is the principal cholesterol carrier in brain. The ε4 allele of the APOE gene is 
the most robust genetic risk factor for sporadic AD. Recently, large genome-wide association studies 
have classified cholesterol metabolism-related genes, including, ABCA7 (ATP binding cassette 
subfamily A member 7), ABCG1 (ATP binding cassette subfamily G member 1), CLU (apolipoprotein J) 
and SORL1 (LDLR relative with 11 ligand-binding repeats), as susceptibility loci [33], while Picard et al 
have found expression levels of the rs2269657 allele of SREBF2, the gene that codes for sterol 
regulatory element-binding protein-2 (SREBP-2), in frontal cortex from late-onset AD brain to be 
inversely correlated with plaque density and with age at death [34]. In combination this data 
strongly links cholesterol biochemistry to AD. 
Oxysterol levels have been measured in cerebrospinal fluid (CSF) of AD patients and controls mostly 
by GC-MS methods which include a hydrolysis step to hydrolyse fatty acyl esters. 24S-HC was found 
to be elevated in CSF from AD patients [35]. This was explained by enhanced degeneration of 
neuronal cells leading to increased levels of 24S-HC in the CSF [35]. In contrast, GC-MS studies found 
a reduction of 24S-HC in plasma of AD patients. This apparent contradiction is explained by a 
reduced flux of 24S-HC across the BBB, with plasma 24S-HC concentrations reflecting the reduced 
number of metabolically active neurons [35]. In a recent study using LC-ESI-MS methods 
incorporating Girard P (GP)-derivatisation we found no difference in the level of non-esterified 24S-
HC in AD and control CSF. The concentration of the non-esterified molecule in CSF is extremely low 
(0.02 ng/mL) making accurate measurement of small changes difficult. However, cholestenoic acids 
are more abundant in CSF and we have recently found 7α,25-dihydroxy-3-oxocholest-4-en-26-oic 
acid (7α,25-diH,3O-CA, Figure 3) to be reduced in AD CSF compared to controls. 
C24 bile acids have also been implicated in AD. Using LC-MS/MS methods Marksteiner et al found 
levels of lithocholic acid were significantly enhanced in plasma of AD patients (50 ± 6 nM,  p = 0.004) 
compared to healthy controls (32 ± 3 nM) [16]. This is a particularly interesting finding as lithocholic 
acid is usually considered as a secondary bile acid derived from bacterial reduction of 
chenodeoxycholic acid. In contrast, Pan et al, also using LC-MS/MS, found significantly lower cholic 
acid concentrations in plasma of AD patients compared to age-matched control subjects (p = 0.03), 
but did not find enhanced lithocholic acid levels [15]. Like-wise, the findings of Pan et al [15] were 
not confirmed by the data of Marksteiner et al [16]. More careful studies are required to remedy 
these contradictions. Perhaps, the modern investigator should re-consider their methods of bile acid 
extraction and remember the great care taken by earlier workers in this regard [3, 6]. 
Many studies have linked abnormal lipid metabolism and lysosomal dysfunction to PD [36]. In this 
context Björkhem and colleagues, again using GC-MS following hydrolysis, found that plasma levels 
of 24S-HC and (25R)26-hydroxycholesterol (26-HC) were in the normal range, however, in CSF the 
level of 24S-HC correlated with disease duration, although 24S-HC levels in 90% of patients were 
within the normal range of concentrations [37]. Cheng et al, also using GC-MS following hydrolysis, 
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analysed the oxysterol content of PD brain [38]. Of the regions analysed, the visual cortex (VC) 
showed the most significant changes in oxysterol levels [38]. Cheng et al found increases in 7α-
hydroxycholesterol (7α-HC), 7β-hydroxycholesterol (7β-HC), 5β,6-epoxycholesterol (5β,6-EC), 7-
oxocholesterol (7-OC), 26-HC and 24S-HC in PD VC (Figure 3). While 24S-HC and 26-HC are formed 
enzymatically from cholesterol by the cytochrome P450 (CYP) enzymes CYP46A1 and CYP27A1, 
respectively, and both enzymes are expressed in brain, 7α-HC, 7β-HC and 7-OC can be formed by 
CYP7A1. CYP7A1 is liver specific and will 7α-hydroxylate cholesterol to give 7α-HC, introduce a 7-oxo 
group to 7-dehydrocholesterol (7-DHC) to give 7-OC, which can be then be reduced by 
hydroxysteroid dehydrogenase (HSD) 11B1 to 7β-HC [39]. These three sterols could conceivably 
cross the BBB and enter the brain from the circulation. Alternatively, 7α-HC, 7β-HC, 7-OC and also 
5,6-EC can be formed by non-enzymatic oxidation reactions of cholesterol perhaps in vivo as a 
consequence of oxidative stress or ex vivo during sample handling procedures. 
Gaucher’s disease is an autosomal recessive lysosomal storage disorder. It is caused by mutations in 
the glucoceribrosidase (GBA) gene. Mutations in GBA constitute the most common risk factor 
identified for PD to-date [40]. Another autosomal recessive lysosomal storage disorder, Niemann-
Pick (NP) type A and B, which results from mutations in the sphingomyelin phosphodiesterase 1 
(SMPD1) gene is also reported as a risk-factor for PD [41], while heterozygous carriers of the 
autosomal recessive lysosomal storage disorder NP type C1 (NPC1), with mutations in the NPC1 
gene, have also been reported to present with PD [42]. Furthermore, oligomeric α-synuclein 
associated with PD development is increased in plasma from patients with Gaucher’s disease, NPC 
and also Wolman disease (infant lysosomal lipase, LIPA, deficiency), yet another lysosomal storage 
disorder [43]. Cellular cholesterol is reported to influence the severity of Gaucher’s disease [44], 
while patients with NPA, NPC, Wolman disease and carriers of NPC1 each show elevated plasma 
levels of oxysterols derived from non-enzymatic reactions, or their down-stream metabolites, 
perhaps implicating these molecules with PD [39, 45, 46]. These data point to a need for large scale 
studies of patients with Gaucher’s disease and those with PD to investigate levels of non-
enzymatically derived oxysterols and their metabolites.        
3.1.2 Motor Neuron Disease 
Oxysterols have been repeatedly linked to motor neuron neurodegeneration [47]. There is 
convincing evidence for their involvement in the loss of motor neurons, particularly in the disorder 
hereditary spastic paraplegia type 5 (SPG5). SPG5 is a rare autosomal recessive disorder caused by 
mutations in CYP7B1, the gene encoding oxysterol 7α-hydroxylase, and SPG5, like other hereditary 
spastic paraplegias, is characterised by progressive neurodegeneration of corticospinal tract motor 
neurons. SPG5 is biochemically defined by elevated levels of 25-hydroxycholesterol (25-HC), 26-HC 
and 3β-hydroxycholest-5-en-(25R)26-oic acid (3β-HCA) in serum/plasma and CSF [47-49]. In a recent 
study, using GC-MS following base hydrolysis, Schöls et al found that the serum concentration of 26-
HC, measured by GC-MS as a sum of its esterified and non-esterified forms, correlated with disease 
severity and duration [47]. Furthermore, 24S-HC, 25-HC, 26-HC and 3β-HCA were found to be 
cytotoxic towards cortical neurons derived from human induced pluripotent stem cells (iPSCs) and a 
motor neuron-like cell line NSC-34 [47]. In vivo and in vitro studies by Theofilopoulos et al have 
shown that 3β-HCA is toxic towards oculomotor neurons in mouse, while the product of its 
metabolism by CYP7B1, 3β,7α-dihydroxycholest-5-en-(25R)26-oic acid (3β,7α-diHCA), is protective 
towards oculomotor neurons in the developing mouse [48]. Interestingly, the 7β-epimer, 3β,7β-
dihydroxycholest-5-en-(25R)26-oic acid (3β,7β-diHCA), which is not down regulated in SPG5 human 
plasma or CSF, was toxic towards oculomotor neurons in mice [48]. 3β,7β-diHCA is likely to be 
formed from 3β-hydroxy-7-oxocholest-5-en-(25R)26-oic acid (3βH,7O-CA) in a reaction catalysed by 
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the enzyme HSD11B1 [39]. 3βH,7O-CA was found to promote the maturation of oculomotor neurons 
in developing mouse and zebrafish [48]. In a recent “sterolomic” study performed by Abdel-Khalik et 
al using LC-MS with multistage fragmentation (MS
n
) and exploiting GP-derivatisation technology, the 
concentration of non-esterified cholesterol was found to elevated in CSF of patients suffering from 
amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease, and when 
normalised to cholesterol the concentrations of 3β,7α-diHCA and 3β,7β-diHCA were found to be 
reduced, so was 3β-HCA but not 26-HC [50]. Both the studies performed by Theofilopoulos et al and 
Abdel-Khalik et al exploited LC-MS(MS
n
) with GP-derivatisation [48, 50]. 
3.2. Inborn Errors of Metabolism 
In section 3.1.1 the autosomal recessive inborn errors of metabolism classified as NP disease were 
referred to. NPA (presenting in early infancy) and NPB (presenting in children) are both caused by 
mutations in the SMPD1 gene, while NPC1 and NPC2 are caused by mutations in the genes NPC1 and 
NPC2, respectively. The NP diseases are characterised by enhanced levels of oxysterols derived by 
non-enzymatic oxidation reactions. Analysis of plasma for the primary metabolites, 7-OC and 
cholestane-3β,5α,6β (3β,5α,6β-triol), by either GC-MS or LC-MS/MS with derivatisation, can 
diagnose NP diseases [51-53]. However, both metabolites can be generated ex vivo from reaction 
with atmospheric oxygen, so neither is ideal for disease diagnoses. 7-OC can be metabolised in vivo 
to 3β,7β-dihydroxychol-5-en-24-oic acid and subsequently conjugated with sulphuric acid at C-3, N-
acetylglucosamine at C-7β and also glycine or taurine at C-24 and could provide a provide a urinary 
diagnostic (Figure 3) [39, 54]. This unusual bile acid is also found elevated in urine and plasma from 
Smith-Lemli-Opitz syndrome (SLOS) patients (see below), however, Clayton and colleagues found 
that the UGT3A1 gene, coding 7β-hydroxy-bile acid UDP N-acetylglucosaminyl transferase, shows a 
common mutation, c.T361G/p.C121G, resulting in inactivity of the enzyme [54], indicating that this is 
not an optimal diagnostic for NP or SLOS diseases. Alternatively, the end product of 3β,5α,6β-triol 
metabolism may provide a better diagnostic for NPC and Clayton’s group in London and Ory’s group 
in Washington using LC-MS/MS methods found 3β,5α,6β-trihydroxycholanoyl-glycine to be elevated 
in NPC plasma and dried blood spots [46, 54]. We have found the unconjugated acid 3β,5α,6β-
trihydroxycholan-24-oic acid to be elevated also in patients with the autosomal recessive lysosomal 
storage disorder, lysosomal acid lipase deficiency (LALD), caused by mutations in the LIPA (lysosomal 
acid lipase) gene [45]. 
Two other autosomal recessive inborn errors of metabolism, presenting with quite different clinical 
features from the lysosomal storage disorders, but also showing elevated plasma levels of 7-OC in 
some patients are SLOS and cerebrotendinous xanthomatosis (CTX) [55]. In the case of SLOS, where 
the cause of the disorder is deficiency in the enzyme 7-dehydrocholesterol reductase (DHCR7) and 
main biochemical feature is elevated levels of the cholesterol precursor 7-DHC, the origin of 7-OC is 
likely to be the enzymatic oxidation of 7-DHC to 7-OC by CYP7A1 [39]. In SLOS, like NPC, 7-OC can be 
metabolised to 3β,7β-dihydroxycholest-5-en-24-oic acid and its conjugates. SLOS is usually 
diagnosed by an elevated 7-DHC to cholesterol ratio in plasma, either by GC-MS or LC-MS/MS, but 
conjugated 3β,7β-dihydroxycholest-5-en-24-oic acid may provide a urinary diagnostic, perhaps even 
from the mother prenatally. In CTX, caused by deficiency in the enzyme CYP27A1, essential to the 
acidic pathway of bile acid biosynthesis, CYP7A1 is up-regulated as a consequence of reduced 
negative-feedback by primary bile acids and it is probable that 7-OC is formed enzymatically by up-
regulated CYP7A1 using 7-DHC as a substrate. CTX is usually diagnosed in adulthood, biochemically 
by elevated plasma levels of cholestanol using GC-MS, however, as a treatment exists (oral 
chenodeoxycholic acid therapy), there is a need for early diagnosis preferably from dried blood spots 
from infants. 
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deBarber and Vaz and colleagues have developed a 2 min LC-MS/MS method targeting 7α,12α-
dihydroxycholest-4-en-3-one (7α,12α-diHCO) in newborn dried blood spots with only a 2 min 
extraction time [56]. 7α,12α-diHCO is elevated in CTX as a consequence of upregulated CYP7A1 and 
also sterol 12α-hydroxylase (CYP8B1). They exploited derivatisation of the 3-oxo group with (O-(3-
trimethylammoniumpropyl) hydroxylamine) bromide to give a charged oxime (Figure 2) [56]. The 
derivative gives an intense [M]
+
 ion and a strong transition for multiple reaction monitoring. An 
alternative derivative exploited by deBarber et al in an earlier study is the GP reagent [57]. Most 
recently, Vaz deBarber and colleagues have used MS/MS with flow-injection to diagnose CTX in a 2 
min run from dried blood spots [58]. They measured the ratio between cholestanetetrol-glucuronide 
(probably, 5β-cholestane-3α,7α,12α,25-tetrol-glucuronide) and taurochenodeoxycholic acid. In term 
and pre-term infants the ratio was in the range 0 – 0.061 while in CTX patients the range was 0.8 – 
866, the absence of an overlap in the ranges suggests this may provide a good diagnostic test for 
CTX. Zellweger syndrome is a peroxisomal disorder and can also lead to elevated plasma levels of 
cholestanetetrol-glucuronide but is readily differentiated from CTX by measuring the 
cholestanetetrol-glucuronide to taurochenodeoxycholic acid ratio, giving values similar to term and 
preterm infants [58]. 
Acyl CoA Oxidase 2 (ACOX2) is a peroxisomal enzyme involved in the side-chain shortening of C27 bile 
acid precursors to primary C24 acids. Vilharino et al described the first case of human deficiency only 
recently [59]. The patient presented with liver fibrosis, mild ataxia and cognitive impairment [59]. 
The disease was diagnosed by exome sequencing. The biochemical phenotype was established by 
LC-MS/MS, where elevated plasma and urine levels of 3α,7α-dihydroxy-5β-cholestan-26-oic and 
3α,7α,12α-trihydroxy-5β-cholestan-26-oic acids, mostly as taurine conjugates, were evident. The 
patient’s plasma level of the taurine conjugate of the latter acid was about 25 times greater than the 
normal upper limit. His heterozygote parents, showed normal levels of C27 acids [59]. Since the first 
report by Vilharino et al [59], two further patients have been diagnosed with ACOX2 deficiency [60, 
61]. An adolescent boy (16 years) and his younger sister (13 years) were found by LC-MS/MS to have 
elevated levels of taurodihydroxycholestanoic and taurotrihydroxycholestanoic acids in serum [60]. 
Both the 25R- and 25S-acids were observed, suggesting a defect in ACOX2. Genetic analysis revealed 
a missense mutation in ACOX2 in both siblings. Surprisingly, while the male showed elevation of 
serum transaminases levels, a biochemical sign of liver damage, his  sister exhibited normal serum 
transaminases levels, a fact that might reflect sex-related sensitivity to toxic C27 bile acids [60]. A 
further patient with ACOX2 deficiency has been identified who passed away at 5 months of age [61]. 
Using LC-MS she was found to have high plasma levels of primary bile acids consistent with 
cholestatic liver disease, and also elevated taurine conjugated trihydroxycholestanoic, 
trihydroxycholestenoic acid and tetrahydroxycholestanoic acids, suggestive of a peroxisomal 
disorder [61]. Genetic testing confirmed ACOX2 deficiency. 
Other disorders of cholesterol metabolism and bile acid biosynthesis can be defined by LC-MS, LC-
MS/MS or DI-MS, although final diagnosis should be confirmed by gene sequencing and the 
interested reader is directed to the excellent review by Vaz and Ferdinanusse [62]. 
The diagnosis of many rare inborn errors of metabolism is still hindered by the lack of available 
standards with semi-quantitative approaches still used for diagnosis. The field of “Sterolomics” has 
enabled the identification of many promising markers of disease, with an ultimate goal that these 
markers should move on to be used in high-quality quantitative clinical diagnostic tests.                 
4. Conclusions 
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“Sterolomics” is a growing field as ever more biochemical activities of cholesterol metabolites are 
being uncovered. The extreme diversity of cholesterol metabolism and the huge number of potential 
biosynthetic products dictates a need for unbiased investigations alongside more established 
targeted protocols. An important consideration for all investigators in the field is the degree of 
chemical identity reported in publications. Mass spectrometry identifications are seldom 
unequivocal and often rely on a knowledge of underlying biochemistry. It is recommended that all 
assumption are indicated in manuscripts, perhaps as part of supplemental information.     
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Figure Captions 
Figure 1. Examples of members of the sterol family. Cholesterol, 24S-hydroxycholesterol, 3β-
hydroxycholest-5-en-(25R)26-oic acid, 25-hydroxyvitamin D3, chenodeoxycholic acid (3α,7α-
dihydroxy-5β-cholan-24-oic acid), pregnenolone, dehydroepiandrosterone, 17β-estradiol. 
Figure 2. Derivatisation with charge-tagging reagents. (A) Derivatisation of a ketosterol (7α,12α-
dihydroxycholest-4-en-3-one) with Girard T (GT) or Girard P (GP) reagent increases the sterol mass 
by 114.1026 Da or 134.0713 Da. (B) Derivatisation of a 3-hydroxy group, after oxidation to a ketone, 
by [
2
H9]GT or [
2
H5]GP reagent increases the sterol mass by 121.1434 Da or 137.087 Da. (C) 
Derivatisation of a ketosterol (7α,12α-dihydroxycholest-4-en-3-one) with (O-(3-
trimethylammoniumpropyl) hydroxylamine increase the sterol mass by 115.123 Da. 
Figure 3. Structures of different oxysterols of potential diagnostic value. Where a defective enzyme 
leads to a disease, the relevant disease is indicated below the enzyme in blue preceded by an X. 
Where a metabolite may be diagnostic of a disease, the relevant disease is written in red, with an 
arrow indicating if the metabolite is of enhanced or reduced abundance. Broken lines connecting 
metabolites indicate that multiple enzyme catalysed reactions are involved.     
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Exact Mass: 316.2402
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Chemical Formula: C19H28O2
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Exact Mass: 272.1776
17 -Estradiol (LMST02010001)
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7-Dehydrocholesterol (LMST01010069)
Chemical Formula: C27H44O
Exact Mass: 384.3392
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Chemical Formula: C27H44O2
Exact Mass: 400.3341
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7 -Hydroxycholesterol (LMST01010047)
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Chemical Formula: C27H46O
Exact Mass: 386.3549
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Chemical Formula: C27H46O2
Exact Mass: 402.3498
5,6-Epoxycholesterol
Chemical Formula: C27H48O3
Exact Mass: 420.3603
Cholestane-3 ,5 ,6 -triol (LMST01010052)
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Chemical Formula: C27H46O2
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Chemical Formula: C27H46O2
Exact Mass: 402.3498
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Chemical Formula: C27H44O4
Exact Mass: 432.3240
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Chemical Formula: C26H43NO6
Exact Mass: 465.3090
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Chemical Formula: C29H51NO7S
Exact Mass: 557.3386
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3 ,7 -Dihydroxycholest-5-en-(25R)26-oic acid (LMST04030148)
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3 ,7 ,12 -Trihydroxy-5 -cholestanoyltaurine
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Chemical Formula: C34H54N2O13S
Exact Mass: 730.3347
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Chemical Formula: C27H44O3
Exact Mass: 416.3290
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7 ,12 -Dihydroxycholest-4-en-3-one
(LMST04030114)
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Chemical Formula: C27H42O5
Exact Mass: 446.3032
AD
7 ,25-Dihydroxy-3-oxocholest-4-en-26-oic acid
3 -Sulfoxy-7 -N-acetylglucosaminyl-
chol-5-enoylglycine
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• Sterolomics: profile all metabolites derived from cholesterol and cyclic precursors 
• Discussion of different mass spectrometry methods used in sterolomics 
• Sterolomics for disease diagnosis 
• Sterolomics and inborn errors of metabolism 
